The Abuse Potential of Remoxy<sup>®</sup>, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone
Beatrice Setnik, Lynn R. Webster(Adherent Technologies (United States)), Jody M. Cleveland(Pfizer (United States)), Carl L. Roland(Pfizer (United States))
Cited by 42
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304